keyword
MENU ▼
Read by QxMD icon Read
search

fibrosis hcv

keyword
https://www.readbyqxmd.com/read/29136329/follow-up-of-sustained-virologic-responders-with-hepatitis-c-and-advanced-liver-disease-after-interferon-ribavirin-free-treatment
#1
Karin Kozbial, Stephan Moser, Ramona Al-Zoairy, Remy Schwarzer, Christian Datz, Rudolf Stauber, Hermann Laferl, Michael Strasser, Sandra Beinhardt, Albert Friedrich Stättermayer, Michael Gschwantler, Heinz Zoller, Andreas Maieron, Ivo Graziadei, Michael Trauner, Petra Steindl-Munda, Harald Hofer, Peter Ferenci
BACKGROUND: The introduction of direct-acting antivirals (DAA) has increased sustained virological response (SVR) rates in patients with advanced liver disease and chronic hepatitis C(CHC)infection. At present, data on clinical outcome and long-term durability of viral eradication after successful DAA therapy are scarce. AIM: To evaluate the long-term success of viral eradication in patients with advanced fibrosis or cirrhosis treated with DAAs. METHODS: Five hundred and fifty one patients with advanced fibrosis (n=158) or liver cirrhosis (CPS-A:317,CPS-B/C:76) and SVR after interferon and ribavirin-free DAA therapy treated between October 2013 and April 2016 were studied with a median follow-up of 65...
November 14, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/29135574/interferon-free-therapy-for-treating-hcv-in-difficult-to-treat-hiv-coinfected-patients-as-implemented-in-routine-medical-practice
#2
Carlos Mínguez, Miguel García-Deltoro, Juan Flores, Maria-José Galindo, Marta Montero, Sergio Reus, Jorge Carmena, Mar Masiá, Concepción Amador, Enrique Ortega
BACKGROUND/AIMS: Data regarding the use of all-oral direct-acting antivirals (DAA) in HIV/HCV-coinfected patients with advanced liver fibrosis are required, because they are generally under-represented in clinical trials. This study sought to evaluate the use of these drugs in a cohort of coinfected patients, mostly with factors that have previously been recognised as predictors of treatment failure. METHODS: COINFECOVA-2 is an observational, multicenter study conducted in Eastern Spain...
November 10, 2017: AIDS
https://www.readbyqxmd.com/read/29135370/pharmacokinetics-based-adjusted-versus-standard-dose-of-ribavirin-does-not-improve-virologic-response-rates-in-chronic-hepatitis-c-genotype-4-patients-a-randomized-controlled-trial
#3
Ibrahim H Altraif, Faisal Sanai, Mohammed A Babatin, Abduljaleel A Alalwan, Ayman A Abdo, Waleed Alhamoudi, Musthafa Peedikayil, Hamdan Alghamdi, Fahad Alsohaibani, Khalid A Alswat, Shazia Murtaza, Abdullah Alghamdi, Sara Altraif, Abdulrahman Aljumah, Fayaz A Handoo, Abdulkareem M AlBekairy, Hamad I Al-Ashgar, Mohammed Alquaiz, Mohammed A Alblawi, Waleed AlTamimi, Véronique Loustaud-Ratti, Pierre Marquett
Optimal doses of Ribavirin (RBV) for hepatitis C virus (HCV) treatment are not known. To assess the safety and efficacy of PegIFNalfa-2a in combination with an adjusted (ADJ) RBV dose based on early pharmacokinetics versus a fixed standard (STD) dose of RBV in chronic HCV genotype (GT) 4-naive patients in a randomized trial. One hundred eighty-one patients were randomized. The baseline variables were similar in both arms and females were 50.3% of the patients, 76.5% had minimal-moderate fibrosis (F0-2). Sustained virologic response (SVR) was achieved in 99 (54...
November 2017: Journal of Interferon & Cytokine Research
https://www.readbyqxmd.com/read/29135030/hepatitis-c-virus-clearance-in-older-adults
#4
Antonio Massimo Ippolito, Angelo Iacobellis, Michele Milella, Fabio Conti, Vincenzo Messina, Maria Rosa Valvano, Grazia Anna Niro, Filomena Morisco, Michele Barone, Antonio Patrizio Termite, Giuseppina Brancaccio, Angelo Andriulli
OBJECTIVES: To determine whether older adults with the hepatitis C virus (HCV) achieve a sustained viral response (SVR) after treatment with direct-acting antiviral therapy. PARTICIPANTS: Individuals aged 80 and older with chronic HCV infection (N = 253; n = 213 with cirrhosis, n = 40 with advanced fibrosis). MEASUREMENTS: We investigated the efficacy, safety, and global clinical effect of treatment with different combinations of direct antiviral agents (DAAs)...
November 14, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/29132760/hepatitis-c-in-sub-saharan-africa-the-current-status-and-recommendations-for-achieving-elimination-by-2030
#5
REVIEW
Mark W Sonderup, Mary Afihene, Reidwaan Ally, Betty Apica, Yaw Awuku, Lina Cunha, Geoffrey Dusheiko, Neliswa Gogela, Marie-Jeanne Lohouès-Kouacou, Phillip Lam, Olufunmilayo Lesi, Papa Saliou Mbaye, Emmanuel Musabeyezu, Betty Musau, Olesegun Ojo, John Rwegasha, Barbara Scholz, Abate B Shewaye, Christian Tzeuton, Chris Kassianides, C Wendy Spearman
In 2016, WHO adopted a strategy for the elimination of viral hepatitis by 2030. Africa, and more specifically, sub-Saharan Africa, carries a substantial portion of the global burden of viral hepatitis, especially chronic hepatitis B and hepatitis C virus infections. The task that lies ahead for sub-Saharan Africa to achieve elimination is substantial, but not insurmountable. Major developments in the management of hepatitis C have put elimination within reach, but several difficulties will need to be navigated on the path to elimination...
December 2017: Lancet. Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29120573/il-17-induced-the-recruitment-and-functional-activity-of-granulocytes-isolated-from-patients-coinfected-with-schistosoma-mansoni-and-hepatitis-c-virus
#6
Soad Nady, Gamal Esmat
The aim of this study was to investigate the role of Th17 cytokines on granulocytes recruitment and functional activity in Schistosoma mansoni/hepatitis C virus (HCV) co-infected patients. Granulocytes were isolated from the co-infected blood and stimulated overnight with Schistosoma soluble egg antigen (SEA) in the presence of IL-17, IL-22, or both cytokines. In parallel, granuloma was induced in vitro using the isolated granulocytes and SEA-coated polyacrylamide beads in the presence of IL-17 and/or IL-22 then the sizes of granulomas were measured after one week...
January 2017: Egyptian Journal of Immunology
https://www.readbyqxmd.com/read/29113144/modulation-of-cell-death-pathways-by-hepatitis-c-virus-proteins-in-huh7-5-hepatoma-cells
#7
Olga V Masalova, Ekaterina I Lesnova, Pavel N Solyev, Natalia F Zakirova, Vladimir S Prassolov, Sergey N Kochetkov, Alexander V Ivanov, Alla A Kushch
The hepatitis C virus (HCV) causes chronic liver disease leading to fibrosis, cirrhosis, and hepatocellular carcinoma. HCV infection triggers various types of cell death which contribute to hepatitis C pathogenesis. However, much is still unknown about the impact of viral proteins on them. Here we present the results of simultaneous immunocytochemical analysis of markers of apoptosis, autophagy, and necrosis in Huh7.5 cells expressing individual HCV proteins or their combinations, or harboring the virus replicon...
November 6, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/29112304/the-success-of-hcv-cure-every-rose-has-its-thorn
#8
Dominique Salmon-Ceron, Mario U Mondelli, Mojca Maticic, Joop E Arends
This review aimed to examine mid-term liver complications and extra-hepatic clinical syndromes in addition to quality of life benefits associated with achieving HCV cure. Also to review the few safety issues that have been associated with the use of oral direct acting antivirals (DAAs) and discuss the potential benefits of the reduction of the burden of HCV infection at the population level. HCV cure is possible with DAAs in more than 95% of the patients treated. The blockage of liver inflammation and halting of fibrosis progression translates in both hepatic and extra-hepatic beneficial improvements and in reduction in the need for liver transplantation secondary to HCV...
November 7, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29104462/association-of-ifnl3-genotype-with-hepatic-steatosis-in-chronic-hepatitis-c-patients-treated-with-peginterferon-and-ribavirin-combination-therapy
#9
Shingo Nakamoto, Fumio Imazeki, Tatsuo Kanda, Shuang Wu, Masato Nakamura, Shin Yasui, Akinobu Tawada, Rintaro Mikata, Tetsuhiro Chiba, Makoto Arai, Osamu Yokosuka, Hiroshi Shirasawa
BACKGROUND: Genetic variation near the interferon lambda 3 (IFNL3) is known to be associated with response to pegylated interferon (pegIFN) and ribavirin combination therapy in patients with chronic hepatitis C virus (HCV) infection which is often accompanied by hepatic steatosis. AIMS: We examined whether this genetic variation is associated with host lipids and treatment response. METHODS: A total of 101 Japanese patients who had underwent liver biopsy before treatment with pegIFN and ribavirin for HCV genotype 1b infection were retrospectively analyzed for association between IFNL3 genotypes (rs8099917) and clinical factors including histopathological features of the liver...
2017: International Journal of Medical Sciences
https://www.readbyqxmd.com/read/29099423/data-mining-of-routine-laboratory-tests-can-predict-liver-disease-progression-in-egyptian-diabetic-patients-with-hepatitis-c-virus-g4-infection-a-cohort-study-of-71%C3%A2-806-patients
#10
Yasmin Saad, Abobakr Awad, Wafaa Alakel, Wahid Doss, Tahany Awad, Mahasen Mabrouk
OBJECTIVES: Hepatitis C virus (HCV) and diabetes mellitus (DM) are prevalent diseases worldwide, associated with significant morbidity, mortality, and mutual association. The aims of this study were as follows: (i) find the prevalence of DM among 71 806 Egyptian patients with chronic HCV infection and its effect on liver disease progression and (ii) using data mining of routine tests to predict hepatic fibrosis in diabetic patients with HCV infection. PATIENTS AND METHODS: A retrospective multicentered study included laboratory and histopathological data of 71 806 patients with HCV infection collected by Egyptian National Committee for control of viral hepatitis...
November 2, 2017: European Journal of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/29093082/according-to-hcv-infection-stage-il-7-plus-4-1bb-triggering-alone-or-combined-with-pd-1-blockade-increases-traf1-low-hcv-specific-cd8-cell-reactivity
#11
Elia Moreno-Cubero, Dolores Subirá, Eduardo Sanz-de-Villalobos, Trinidad Parra-Cid, Antonio Madejón, Joaquín Miquel, Antonio Olveira, Alejandro González-Praetorius, Javier García-Samaniego, Juan-Ramón Larrubia
Hepatitis C virus (HCV)-specific CD8(+) T cells suffer a progressive exhaustion during persistent HCV infection (PI). This process could involve the positive immune checkpoint 4-1BB/4-1BBL, through the loss of its signal transducer TRAF1. To address this issue, peripheral HCV-specific CD8(+) T cells (Pentamer(+)/CD8(+)) from patients with PI and resolved infection after treatment (RI) were studied. Duration of HCV infection and liver fibrosis progression rate inversely correlated with the likelihood of detecting peripheral pentamer(+)/CD8(+) cells...
November 1, 2017: Journal of Virology
https://www.readbyqxmd.com/read/29091333/disappearance-of-perihepatic-lymph-node-enlargement-after-hepatitis-c-viral-eradication-with-direct-acting-antivirals
#12
Hiromi Hikita, Masaya Sato, Mamiko Sato, Yoko Soroida, Tamaki Kobayashi, Hiroaki Gotoh, Tomomi Iwai, Ryo Nakagomi, Ryosuke Tateishi, Takako Komuro, Shinji Sone, Kazuhiko Koike, Yutaka Yatomi, Hitoshi Ikeda
Perihepatic lymph node enlargement (PLNE) which has been shown to be negatively associated with hepatocellular carcinoma (HCC) occurrence is frequently observed in chronic liver disease, however, changes in the state of perihepatic lymph nodes after eradication of hepatitis C virus (HCV) have not been investigated yet. We aimed to evaluate this issue. We enrolled 472 patients with chronic HCV who achieved viral eradication with direct-acting antivirals (DAA). We investigated whether the status of perihepatic lymph nodes changed before and after HCV eradication (primary endpoint)...
November 1, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29091323/lower-levels-of-dehydroepiandrosterone-sulfate-are-associated-with-more-advanced-liver-fibrosis-in-chronic-hepatitis-c
#13
João Marcello de Araujo Neto, Henrique Sérgio Moraes Coelho, Maria Chiara Chindamo, Guilherme Ferreira da Motta Rezende, Vera Lúcia Nunes Pannain, Adriana Marques Caroli de Freitas Bottino, Luiz Fernando Bruzzi Porto, Ronir Raggio Luiz, Cristiane Alves Villela-Nogueira, Renata M Perez
Chronic infection with the hepatitis C virus induces liver fibrosis, but it is unknown why some patients progress to advanced fibrosis while others remain with mild disease. Recently, an inverse association between serum levels of dehydroepiandrosterone sulphate (DHEA-S) and liver fibrosis in patients with nonalcoholic fatty liver disease was described and it was postulated that dehydroepiandrosterone (DHEA) has anti-fibrotic effects. Our aim was to compare serum DHEA-S levels with liver fibrosis in hepatitis C patients...
November 1, 2017: Journal of Viral Hepatitis
https://www.readbyqxmd.com/read/29089161/association-between-pnpla3-rs738409-c-g-variant-and-hepatocellular-carcinoma-in-asian-chronic-hepatitis-c-patients-a-longitudinal-study
#14
Yi-Hao Yen, Ming-Chao Tsai, Cheng-Kun Wu, Kuo-Chin Chang, Chao-Hung Hung, King-Wah Chiu, Sheng-Nan Lu, Jing-Houng Wang, Chien-Hung Chen, Kwong-Ming Kee, Yuan-Hung Kuo, Po-Lin Tseng, Ming-Tsung Lin, Chao-Min Huang, Jung-Ting Lin, Tsung-Hui Hu
BACKGROUND/PURPOSE: Prdevious meta-analyses assess whether or not patatin-like phospholipase domain containing 3 (PNPLA3) (rs738409 C > G) was associated with increased risk of hepatocellular carcinoma (HCC) in Caucasians patients with hepatitis C virus (HCV)-related cirrhosis, these meta-analyses did not provide firm conclusions. Only one cross-sectional study involving Asian patients has previously been conducted to explore this issue. We aim to investigate this in a longitudinal cohort of Asian chronic hepatitis C (CHC) patients...
October 28, 2017: Journal of the Formosan Medical Association, Taiwan Yi Zhi
https://www.readbyqxmd.com/read/29079574/interferon-regulatory-factor-5-irf5-suppresses-hepatitis-c-virus-hcv-replication-and-hcv-associated-hepatocellular-carcinoma
#15
Ozge Cevik, Dan Li, Erdene Baljinnyam, Dinesh Manvar, Erica M Pimenta, Gulam Waris, Betsy J Barnes, Neerja Kaushik-Basu
Hepatitis C virus (HCV) infection is a major risk factor for the development of chronic liver disease. The disease typically progresses from chronic HCV to fibrosis, cirrhosis, hepatocellular carcinoma (HCC), and death. Chronic inflammation associated with HCV infection is implicated in cirrhosis and HCC, but the molecular players and signaling pathways contributing to these processes remain largely unknown. Interferon regulatory factor 5 (IRF5) is a molecule of interest in HCV-associated HCC because it has critical roles in virus-, Tolllike receptor (TLR)-, and interferon (IFN)- induced signaling pathways...
October 27, 2017: Journal of Biological Chemistry
https://www.readbyqxmd.com/read/29077864/retreatment-with-sofosbuvir-plus-grazoprevir-elbasvir-plus-ribavirin-of-patients-with-hepatitis-c-virus-genotype-1-or-4-who-previously-failed-a-ns5a-or-ns3-containing-regimen-anrs-hc34-revenge
#16
Victor de Lédinghen, Claire Laforest, Christophe Hézode, Stanislas Pol, Alain Renault, Laurent Alric, Dominique Larrey, Sophie Métivier, Albert Tran, Caroline Jézéquel, Didier Samuel, Fabien Zoulim, Christelle Tual, Aurélie Pailhé, Séverine Gibowski, Marc Bourlière, Eric Bellissant, Jean-Michel Pawlotsky
Failure to achieve sustained virological response (SVR) with hepatitis C virus (HCV) direct-acting antiviral-based regimens is commonly associated with emergence of resistance-associated substitutions (RAS). Re-treatment of patients who failed prior direct-acting antivirals remain challenging. The aim of this prospective and randomized study was to evaluate the efficacy (SVR12 primary endpoint) and safety of sofosbuvir + grazoprevir/elbasvir + ribavirin for 16 or 24 weeks in patients who had failed to achieve SVR on previous NS5A or NS3-based therapy and with evidence of RAS at failure...
October 25, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/29077674/macrophage-activation-and-the-tumor-necrosis-factor-cascade-in-hepatitis-c-disease-progression-among-hiv-infected-women-participating-in-the-women-s-interagency-hiv-study
#17
Audrey L French, Jonathan W Martin, Charlesnika T Evans, Marion Peters, Seble G Kessaye, Marek Nowicki, Mark Kuniholm, Elizabeth Golub, Michael Augenbraun, Seema N Desai
BACKGROUND: HIV/hepatitis C-coinfected persons experience more rapid liver disease progression than hepatitis C virus (HCV) monoinfected persons, even in the setting of potent antiretroviral therapy. METHODS: We sought to articulate the role of macrophage activation and inflammation in liver disease progression by measuring serial soluble markers in HIV/HCV-coinfected women. We compared markers measured during retrospectively defined periods of rapid liver disease progression to periods where little or no liver disease progression occurred...
December 1, 2017: Journal of Acquired Immune Deficiency Syndromes: JAIDS
https://www.readbyqxmd.com/read/29065124/sustained-virological-response-halts-fibrosis-progression-a-long-term-follow-up-study-of-people-with-chronic-hepatitis-c-infection
#18
Swee Lin G Chen Yi Mei, Alexander J Thompson, Britt Christensen, Georgina Cunningham, Lucy McDonald, Sally Bell, David Iser, Tin Nguyen, Paul V Desmond
BACKGROUND/AIMS: Long-term follow-up studies validating the clinical benefit of sustained virological response (SVR) in people with chronic hepatitis C (CHC) infection are lacking. Our aim was to identify rates and predictors of liver fibrosis progression in a large, well characterized cohort of CHC patients in whom paired liver fibrosis assessments were performed more than 10 years apart. METHODS: CHC patients who had undergone a baseline liver biopsy pre-2004 and a follow up liver fibrosis assessment more than 10 years later (biopsy or liver stiffness measurement (LSM) using transient elastography [FibroScan]) were identified...
2017: PloS One
https://www.readbyqxmd.com/read/29064081/recommendations-for-the-treatment-of-hepatitis-c-virus-infection-in-chronic-kidney-disease-a-position-statement-by-the-spanish-association-of-the-liver-and-the-kidney
#19
Sami Aoufi-Rabih, Rebeca García-Agudo, María-Carlota Londoño, María-Dolores Fraga-Fuentes, Guillermina Barril-Cuadrado
Hepatitis C virus (HCV) infection is one of the main causes of liver cirrhosis worldwide. The long-term impact of HCV infection is highly variable, ranging from minimal histological changes to extensive fibrosis with hepatocellular carcinoma. The development of HCV drugs has increased dramatically in recent years, even in special populations such as chronic kidney disease patients. Classical treatment of chronic hepatitis C was based on the administration of interferon and ribavirin for 24-48 weeks, which was associated with a poor viral response and a high rate of side effects, especially in patients with a lower estimated glomerular filtration rate...
October 24, 2017: Journal of Nephrology
https://www.readbyqxmd.com/read/29062242/impact-of-hepatitis-c-virus-genotype-4-eradication-following-direct-acting-antivirals-on-liver-stiffness-measurement
#20
Mohammed Tag-Adeen, Ahlam Mohamed Sabra, Yuko Akazawa, Ken Ohnita, Kazuhiko Nakao
BACKGROUND: Liver fibrosis is the most important prognostic factor in chronic hepatitis C virus (HCV) patients, and Egypt shows the highest worldwide HCV prevalence with genotype-4 pre-dominance. The aim of this study was to investigate the degree of liver stiffness measurement (LSM) improvement after successful HCV eradication. PATIENTS AND METHODS: The study included 84 chronic HCV Egyptian patients, and was conducted at Qena University Hospital from November 1, 2015 till October 31, 2016...
2017: Hepatic Medicine: Evidence and Research
keyword
keyword
94653
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"